Author: The Briefing
-
Today’s top deals in biopharma and medtech: 9 Nov 2026
argenx buys Unnatural Products, vVardis sets IPO terms, SRTD Biotech raises a €31.5M seed, Edesa licenses Japan rights to Kyorin and Dipharma buys LogixX Pharma: the deals of 9 November 2026 and why they matter.
-
The week in deals: AI optics, China licensing and defence AI lead, 2 to 8 Nov 2026
Marvell and Lumentum, Boehringer Ingelheim and Sino Biopharm, Shield AI and Echodyne, Aramco and HUMAIN, and Zipline: the biggest deals of the week of 2 to 8 November 2026, one deal explained, and the week ahead.
-
Today’s top deals in AI, energy and biotech: 7 Nov 2026
Harbinger raises $240M, Traversal reaches a $1B valuation, Kalepa raises $75M, Humble Robotics raises $51M and Anaheim Bio launches with €40M: the deals of 7 November 2026 and why they matter.
-
Press review: news from the people on Beginner’s Mind, 7 Nov 2026
Insilico, Last Energy, Ori Biotech, Sofinnova, the EIB and more: twelve months of milestones from guests of Beginner’s Mind.
-
Daily deals archive: biopharma, AI and deep tech
Every daily deals briefing from The Briefing in biopharma, AI, energy, planet and space, newest first, with the lead deal of each day.
-
Today’s top deals in AI, space and biopharma: 6 Nov 2026
Shield AI buys Echodyne for $5.3B, CesiumAstro raises $730M, Zipline raises $1.5B, Evommune licenses a VAV1 degrader and Agility Robotics lists on Nasdaq: the deals of 6 November 2026 and why they matter.
-
Today’s top deals in biopharma, AI and deep tech: 5 Nov 2026
ANI bids $560M for Egetis, T-Therapeutics raises $133M, Marvell buys Lumentum, Alethio raises $90M and Sentra raises $150M: the five deals of 5 November 2026 and why they matter.